Cargando…

Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy

BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianyang, Tang, Yu, Jing, Hao, Sun, Guangyi, Jin, Jing, Liu, Yueping, Song, Yongwen, Wang, Weihu, Fang, Hui, Chen, Bo, Qi, Shunan, Ren, Hua, Li, Ning, Tang, Yuan, Lu, Ningning, Yang, Yong, Yu, Zihao, Wang, Shulian, Li, Yexiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685539/
https://www.ncbi.nlm.nih.gov/pubmed/33228588
http://dx.doi.org/10.1186/s12885-020-07594-7
_version_ 1783613200149774336
author Wang, Jianyang
Tang, Yu
Jing, Hao
Sun, Guangyi
Jin, Jing
Liu, Yueping
Song, Yongwen
Wang, Weihu
Fang, Hui
Chen, Bo
Qi, Shunan
Ren, Hua
Li, Ning
Tang, Yuan
Lu, Ningning
Yang, Yong
Yu, Zihao
Wang, Shulian
Li, Yexiong
author_facet Wang, Jianyang
Tang, Yu
Jing, Hao
Sun, Guangyi
Jin, Jing
Liu, Yueping
Song, Yongwen
Wang, Weihu
Fang, Hui
Chen, Bo
Qi, Shunan
Ren, Hua
Li, Ning
Tang, Yuan
Lu, Ningning
Yang, Yong
Yu, Zihao
Wang, Shulian
Li, Yexiong
author_sort Wang, Jianyang
collection PubMed
description BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world and distinguish individuals who warrant postmastectomy radiotherapy (PMRT). METHODS: Female patients treated from 1999 to 2014 in National Cancer Center of China were retrospectively reviewed. A competing risk model was developed to estimate the cumulative incidence of LRR with death treated as a competing event. RESULTS: A total of 4841 patients were eligible. All underwent mastectomy plus axillary nodes dissection or sentinel node biopsy without PMRT. With a median follow-up of 56.4 months (range, 1–222 months), the 5-year LRR rate was 3.9%.Besides treatment era, age ≤ 40 years old (p < 0.001, hazard ratio [HR] = 2.262), tumor located in inner quadrant (p < 0.001, HR = 2.236), T2 stage (p = 0.020, HR = 1.419), and negative expressions of estrogen receptor (ER) and progesterone receptor (PR) (p = 0.032, HR = 1.485), were patients-related independent risk factors for LRR. The 5-year LRR rates were 1.7, 3.5, and 15.0% for patients with zero, 1–2, and 3–4 risk factors (p < 0.001). CONCLUSIONS: Risk Stratification based on age, T stage, ER/PR status and tumor location can stratify patients with pT1–2 N0 breast cancer into subgroups with different risk of LRR. PMRT might be suggested for patients with 3–4 risk factors.
format Online
Article
Text
id pubmed-7685539
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76855392020-11-25 Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy Wang, Jianyang Tang, Yu Jing, Hao Sun, Guangyi Jin, Jing Liu, Yueping Song, Yongwen Wang, Weihu Fang, Hui Chen, Bo Qi, Shunan Ren, Hua Li, Ning Tang, Yuan Lu, Ningning Yang, Yong Yu, Zihao Wang, Shulian Li, Yexiong BMC Cancer Research Article BACKGROUND: Previous studies have revealed that nearly 15–20% of selected high-risk T1–2N0 breast cancers developed LRR after mastectomy. This study is aim to indentify the risk factors of locoregional recurrence (LRR) in patients with pathologic T1–2N0 breast cancer after mastectomy in a real-world and distinguish individuals who warrant postmastectomy radiotherapy (PMRT). METHODS: Female patients treated from 1999 to 2014 in National Cancer Center of China were retrospectively reviewed. A competing risk model was developed to estimate the cumulative incidence of LRR with death treated as a competing event. RESULTS: A total of 4841 patients were eligible. All underwent mastectomy plus axillary nodes dissection or sentinel node biopsy without PMRT. With a median follow-up of 56.4 months (range, 1–222 months), the 5-year LRR rate was 3.9%.Besides treatment era, age ≤ 40 years old (p < 0.001, hazard ratio [HR] = 2.262), tumor located in inner quadrant (p < 0.001, HR = 2.236), T2 stage (p = 0.020, HR = 1.419), and negative expressions of estrogen receptor (ER) and progesterone receptor (PR) (p = 0.032, HR = 1.485), were patients-related independent risk factors for LRR. The 5-year LRR rates were 1.7, 3.5, and 15.0% for patients with zero, 1–2, and 3–4 risk factors (p < 0.001). CONCLUSIONS: Risk Stratification based on age, T stage, ER/PR status and tumor location can stratify patients with pT1–2 N0 breast cancer into subgroups with different risk of LRR. PMRT might be suggested for patients with 3–4 risk factors. BioMed Central 2020-11-23 /pmc/articles/PMC7685539/ /pubmed/33228588 http://dx.doi.org/10.1186/s12885-020-07594-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wang, Jianyang
Tang, Yu
Jing, Hao
Sun, Guangyi
Jin, Jing
Liu, Yueping
Song, Yongwen
Wang, Weihu
Fang, Hui
Chen, Bo
Qi, Shunan
Ren, Hua
Li, Ning
Tang, Yuan
Lu, Ningning
Yang, Yong
Yu, Zihao
Wang, Shulian
Li, Yexiong
Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title_full Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title_fullStr Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title_full_unstemmed Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title_short Risk stratification for prediction of locoregional recurrence in patients with pathologic T1–2N0 breast cancer after mastectomy
title_sort risk stratification for prediction of locoregional recurrence in patients with pathologic t1–2n0 breast cancer after mastectomy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685539/
https://www.ncbi.nlm.nih.gov/pubmed/33228588
http://dx.doi.org/10.1186/s12885-020-07594-7
work_keys_str_mv AT wangjianyang riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT tangyu riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT jinghao riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT sunguangyi riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT jinjing riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT liuyueping riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT songyongwen riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT wangweihu riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT fanghui riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT chenbo riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT qishunan riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT renhua riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT lining riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT tangyuan riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT luningning riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT yangyong riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT yuzihao riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT wangshulian riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy
AT liyexiong riskstratificationforpredictionoflocoregionalrecurrenceinpatientswithpathologict12n0breastcanceraftermastectomy